Setara Biosciences debuted with $90 million in funding and a lead drug program already in the clinic, aiming at rare neuromuscular disease and a more common bladder condition. The company’s lead program targets Charcot-Marie-Tooth disease type 2C and overactive bladder, using a small molecule that originated from Actio Biosciences—acquired by Jazz Pharmaceuticals. The funding and clinic-stage entry position Setara to progress development while navigating a crowded rare-disease and urology landscape where differentiation and clinical execution are key for partner and payer traction. The report frames the launch as the start of a focused pipeline build centered on a single lead asset derived from prior platform work.